Table 4 Cost effectiveness analysis

Deterministic results (base case)

 DALYs LBW averted

−22.64

 DALYs mod/sev anaemia averted

−1.63

 DALYs MiP averted

−3.56

 Total DALY IPTp-SP

755.1

 Total DALY ISTp-AL

782.93

 Total cost IPTp-SP (US$ 2012)^a

9037.84

 Total cost ISTp-AL (US$ 2012)^a

13,966.84

 Δ Costs (US$ 2012)^a

4929.00

 Δ DALYs

−27.83

 ICER (US$/DALY) ^a

−177.10

Probabilistic results

 DALYs LBW averted

−23.15 (−128.35 to 80.71)

 DALYs mod/sev anaemia averted

−1.63 (−4.35 to 0.94)

 DALYs MiP averted

−3.58 (−5.69 to 1.83)

 Total DALY IPTp-SP

753.55 (631.07 to 895.88)

 Total DALY ISTp-AL

781.91 (657.92 to 928.64)

 Total cost IPTp-SP (US$ 2012)^a

9006.54 (5610.30 to 13,680.56)

 Total cost ISTp-AL (US$ 2012)^a

13,972.79 (10,199.65 to 18,983.86)

 Δ Costs (US$ 2012)^a

4966.25 (3703.53 to 6376.83)

 Δ DALYs

−28.36 (−134.18 to 75.78)

 Average ICER (US$/DALY) ^a

−175.12